Septerna, Inc. Customer Breakdown
Customer relationships and concentrations across all retained periods. Named customers and their revenue are shown when disclosed. Anonymous customers, customer groups and sales channels are labelled separately. Receivable concentration measures unpaid balances, not revenue contribution. A biggest customer by revenue can be identified only from disclosed customer revenue. Missing names and amounts remain missing; identities are not assumed to match between periods.
| Period / as of | Customer / group | Category | Customer revenue | Share of revenue | Share of trade receivables | Basis and limitations |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |